Showing 6921-6940 of 8668 for: Cochrane Systematic Reviews Back
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease
Cochrane Systematic Reviews, 24-Oct-2020
Medications used to treat inflammatory bowel disease (IBD) have significantly improved patient outcomes and delayed time to surgery. However, some of these therapies are recognized to increase the general risk of infection and have an unclear impact on po
- Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
Cochrane Systematic Reviews, 24-Aug-2018
The presence of deleterious mutations in breast cancer 1 gene (BRCA1) or breast cancer 2 gene (BRCA2) significantly increases the risk of developing some cancers, such as breast and high-grade serous cancer (HGSC) of ovarian, tubal and peritoneal origin.
- Risk‐reducing mastectomy for the prevention of primary breast cancer
Cochrane Systematic Reviews, 5-Apr-2018
Recent progress in understanding the genetic basis of breast cancer and widely publicized reports of celebrities undergoing risk-reducing mastectomy (RRM) have increased interest in RRM as a method of preventing breast cancer. This is an update of a Cochr
- Risk‐reducing medications for primary breast cancer: a network meta‐analysis
Cochrane Systematic Reviews, 29-Apr-2019
Breast cancer is the most frequently occurring malignancy and the second cause of death for cancer in women. Cancer prevention agents (CPAs) are a promising approach to reduce the burden of breast cancer. Currently, two main types of CPAs are available: s
- Risk‐scoring systems for predicting preterm birth with the aim of reducing associated adverse outcomes
Cochrane Systematic Reviews, 22-Oct-2015
Identification of pregnancies that are higher risk than average is important to allow the possibility of interventions aimed at preventing adverse outcomes like preterm birth. Many scoring systems designed to classify the risk of a number of poor pregnanc
- Risperidone (depot) for schizophrenia
Cochrane Systematic Reviews, 14-Apr-2016
Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation.
- Risperidone alone or in combination for acute mania
Cochrane Systematic Reviews, 25-Jan-2006
Risperidone, an atypical antipsychotic, is used to treat mania both alone and in combination with other medicines.
- Risperidone dose for schizophrenia
Cochrane Systematic Reviews, 7-Oct-2009
Risperidone is a widely used antipsychotic drug for people with schizophrenia. It is important to get a balance between gaining the most positive effects for the least negative outcomes. The optimal dose of risperidone is the focus of this review.
- Risperidone for attention‐deficit hyperactivity disorder in people with intellectual disabilities
Cochrane Systematic Reviews, 15-Apr-2009
Attention deficit hyperactivity disorder (ADHD) is increasingly recognised as occurring in people with intellectual disability (ID), although treatment of ADHD in this population has not ben tested widely. Risperidone has been used to treat ADHD in people
- Risperidone for autism spectrum disorder
Cochrane Systematic Reviews, 21-Oct-2009
Autistic spectrum disorder encompasses a wide variety of behavioural and communicative problems. Both the core features and non-core features of autism have been targeted in a variety of therapies. Atypical antipsychotic medications, including risperidone
- Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation)
Cochrane Systematic Reviews, 10-Apr-2018
Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggressio
- Risperidone in long-term treatment for bipolar disorder
Cochrane Systematic Reviews, 5-Nov-2008
Risperidone, an atypical antipsychotic, is used to treat acute manic episodes, particularly when psychotic symptoms are present. Drugs used to treat mania are often continued as long-term treatment to prevent relapse. There is a need for evidence of the e
- Risperidone versus olanzapine for schizophrenia
Cochrane Systematic Reviews, 14-Feb-2010
Antipsychotic medication is a mainstay of treatment for schizophrenia. Risperidone and olanzapine are popular choices among the new generation drugs.
- Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse
Cochrane Systematic Reviews, 22-Jan-2018
Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI.
- Risperidone versus other atypical antipsychotic medication for schizophrenia
Cochrane Systematic Reviews, 20-Sep-2016
Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional a
- Risperidone versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 12-Dec-2012
In many countries of the industrialised world second-generation ("atypical") antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs diffe
- Risperidone versus placebo for schizophrenia
Cochrane Systematic Reviews, 15-Dec-2016
Risperidone is the first new-generation antipsychotic drug made available in the market in its generic form.
- Risperidone versus typical antipsychotic medication for schizophrenia
Cochrane Systematic Reviews, 22-Apr-2003
Risperidone is one of the 'new generation' antipsychotics. As well as its reputed tendency to cause fewer movement disorders than the older drugs such as chlorpromazine and haloperidol, it is claimed that risperidone may improve negative symptoms.
- Rituximab as maintenance therapy for patients with follicular lymphoma
Cochrane Systematic Reviews, 15-Apr-2009
Rituximab, a monoclonal anti-CD20 antibody, in combination with chemotherapy improves overall survival compared to chemotherapy alone when used for induction therapy for patients with newly diagnosed or relapsed indolent lymphoma. Randomised controlled tr
- Rituximab for eradicating inhibitors in people with acquired haemophilia A
Cochrane Systematic Reviews, 23-Aug-2021
Acquired haemophilia A is a rare bleeding disorder caused by the development of specific autoantibodies against coagulation factor VIII. Standard treatment, usually steroids alone, or in combination with cyclophosphamide, aims to stop acute bleeds by usin
